PROKIDNEY ($PROK) posted quarterly earnings results on Tuesday, August 12th. The company reported earnings of -$0.13 per share, beating estimates of -$0.15 by $0.02. The company also reported revenue of $221,000, beating estimates of $0 by $221,000.
You can see Quiver Quantitative's $PROK stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
PROKIDNEY Insider Trading Activity
PROKIDNEY insiders have traded $PROK stock on the open market 8 times in the past 6 months. Of those trades, 7 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $PROK stock by insiders over the last 6 months:
- EMPRESARIAL DE CAPITALES S.A. DE C.V. CONTROL has made 7 purchases buying 2,282,616 shares for an estimated $1,519,322 and 0 sales.
- DARIN J. WEBER (Chief Regulatory Officer) sold 103,480 shares for an estimated $312,509
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
PROKIDNEY Hedge Fund Activity
We have seen 27 institutional investors add shares of PROKIDNEY stock to their portfolio, and 47 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 5,000,177 shares (-73.9%) from their portfolio in Q2 2025, for an estimated $2,960,604
- VANGUARD GROUP INC removed 3,643,955 shares (-69.9%) from their portfolio in Q2 2025, for an estimated $2,157,585
- MORGAN STANLEY removed 3,636,134 shares (-26.0%) from their portfolio in Q1 2025, for an estimated $3,185,980
- JPMORGAN CHASE & CO added 1,615,243 shares (+3024.9%) to their portfolio in Q2 2025, for an estimated $956,385
- GEODE CAPITAL MANAGEMENT, LLC removed 1,310,149 shares (-56.4%) from their portfolio in Q2 2025, for an estimated $775,739
- GSA CAPITAL PARTNERS LLP added 510,615 shares (+inf%) to their portfolio in Q2 2025, for an estimated $302,335
- Y-INTERCEPT (HONG KONG) LTD added 351,622 shares (+inf%) to their portfolio in Q2 2025, for an estimated $208,195
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
PROKIDNEY Analyst Ratings
Wall Street analysts have issued reports on $PROK in the last several months. We have seen 2 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 07/15/2025
- Citigroup issued a "Buy" rating on 07/09/2025
- B of A Securities issued a "Underperform" rating on 06/30/2025
To track analyst ratings and price targets for PROKIDNEY, check out Quiver Quantitative's $PROK forecast page.
PROKIDNEY Price Targets
Multiple analysts have issued price targets for $PROK recently. We have seen 4 analysts offer price targets for $PROK in the last 6 months, with a median target of $7.5.
Here are some recent targets:
- Eliana Merle from UBS set a target price of $8.0 on 07/15/2025
- Vamil Divan from Guggenheim set a target price of $7.0 on 07/14/2025
- Yigal Nochomovitz from Citigroup set a target price of $9.0 on 07/09/2025
- Jason Gerberry from B of A Securities set a target price of $1.0 on 06/30/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
